Moreover, it was found that immune-desert or immune-excluded tumours, which are resistant to anti-PD-1/PD-L1 therapy, could benefit from anti-TGF-β/PD-L1 combined therapy [30]. This evidence concerns the gene TGFB1 and neoplasm.